α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition

Yumin Kim, Soyoung Hwang, Roza Khalmuratova, Sunah Kang, Mingyu Lee, Youngjun Song, Jong Wan Park, Jaehoon Yu, Hyun Woo Shin, Yan Lee

Research output: Contribution to journalArticle

Abstract

In the present study, we examined the potential of cell-penetrating peptide (CPP)-based intranasal drug delivery for the treatment of localized nasal diseases. Many charged or non-hydrophobic drugs have difficulty penetrating into the nasal epithelium due to intrinsic membrane impermeability and rapid mucociliary clearance in the nasal cavity. To treat chronic rhinosinusitis with nasal polyps (CRSwNP), one of the most common localized nasal diseases, we conjugated resveratrol (RSV) to an amphiphilic α-helical leucine (L)- and lysine (K)-rich CPP (LK) and intranasally delivered it to the interior of nasal epithelial cells for inhibiting epithelial-to-mesenchymal transition (EMT) caused by hypoxia-inducible factor 1α. The RSV-LK conjugate could penetrate into the nasal epithelium and efficiently inhibit EMT, nasal polyp formation, epithelial disruption, and related inflammation in an eosinophilic CRSwNP mouse model, at 10-fold lower doses and with 3-fold less frequent administration than free RSV. Due to the rapid penetration into the nasal epithelium and the therapeutic effect of the RSV-LK conjugate at much lower doses than free RSV, this CPP-based delivery system, with the ability to overcome the tight nasal epithelial barrier, may provide a new strategy for the treatment of localized nasal diseases without the systemic side effects of cargo drugs.

Original languageEnglish
Pages (from-to)181-194
Number of pages14
JournalJournal of Controlled Release
Volume317
DOIs
StatePublished - 10 Jan 2020

Fingerprint

Cell-Penetrating Peptides
Epithelial-Mesenchymal Transition
Nose
Nose Diseases
Nasal Polyps
Nasal Mucosa
Mucociliary Clearance
Hypoxia-Inducible Factor 1
Nasal Cavity
Therapeutic Uses
Drug-Related Side Effects and Adverse Reactions
Leucine
Pharmaceutical Preparations
Lysine
Epithelial Cells
resveratrol
Inflammation
Membranes

Keywords

  • Cell-penetrating peptide
  • Chronic rhinosinusitis
  • Epithelial-to-mesenchymal transition
  • Intranasal delivery
  • Resveratrol

Cite this

Kim, Yumin ; Hwang, Soyoung ; Khalmuratova, Roza ; Kang, Sunah ; Lee, Mingyu ; Song, Youngjun ; Park, Jong Wan ; Yu, Jaehoon ; Shin, Hyun Woo ; Lee, Yan. / α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition. In: Journal of Controlled Release. 2020 ; Vol. 317. pp. 181-194.
@article{5369c84e356645ce905f935cdc3e4893,
title = "α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition",
abstract = "In the present study, we examined the potential of cell-penetrating peptide (CPP)-based intranasal drug delivery for the treatment of localized nasal diseases. Many charged or non-hydrophobic drugs have difficulty penetrating into the nasal epithelium due to intrinsic membrane impermeability and rapid mucociliary clearance in the nasal cavity. To treat chronic rhinosinusitis with nasal polyps (CRSwNP), one of the most common localized nasal diseases, we conjugated resveratrol (RSV) to an amphiphilic α-helical leucine (L)- and lysine (K)-rich CPP (LK) and intranasally delivered it to the interior of nasal epithelial cells for inhibiting epithelial-to-mesenchymal transition (EMT) caused by hypoxia-inducible factor 1α. The RSV-LK conjugate could penetrate into the nasal epithelium and efficiently inhibit EMT, nasal polyp formation, epithelial disruption, and related inflammation in an eosinophilic CRSwNP mouse model, at 10-fold lower doses and with 3-fold less frequent administration than free RSV. Due to the rapid penetration into the nasal epithelium and the therapeutic effect of the RSV-LK conjugate at much lower doses than free RSV, this CPP-based delivery system, with the ability to overcome the tight nasal epithelial barrier, may provide a new strategy for the treatment of localized nasal diseases without the systemic side effects of cargo drugs.",
keywords = "Cell-penetrating peptide, Chronic rhinosinusitis, Epithelial-to-mesenchymal transition, Intranasal delivery, Resveratrol",
author = "Yumin Kim and Soyoung Hwang and Roza Khalmuratova and Sunah Kang and Mingyu Lee and Youngjun Song and Park, {Jong Wan} and Jaehoon Yu and Shin, {Hyun Woo} and Yan Lee",
year = "2020",
month = "1",
day = "10",
doi = "10.1016/j.jconrel.2019.11.034",
language = "English",
volume = "317",
pages = "181--194",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition. / Kim, Yumin; Hwang, Soyoung; Khalmuratova, Roza; Kang, Sunah; Lee, Mingyu; Song, Youngjun; Park, Jong Wan; Yu, Jaehoon; Shin, Hyun Woo; Lee, Yan.

In: Journal of Controlled Release, Vol. 317, 10.01.2020, p. 181-194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition

AU - Kim, Yumin

AU - Hwang, Soyoung

AU - Khalmuratova, Roza

AU - Kang, Sunah

AU - Lee, Mingyu

AU - Song, Youngjun

AU - Park, Jong Wan

AU - Yu, Jaehoon

AU - Shin, Hyun Woo

AU - Lee, Yan

PY - 2020/1/10

Y1 - 2020/1/10

N2 - In the present study, we examined the potential of cell-penetrating peptide (CPP)-based intranasal drug delivery for the treatment of localized nasal diseases. Many charged or non-hydrophobic drugs have difficulty penetrating into the nasal epithelium due to intrinsic membrane impermeability and rapid mucociliary clearance in the nasal cavity. To treat chronic rhinosinusitis with nasal polyps (CRSwNP), one of the most common localized nasal diseases, we conjugated resveratrol (RSV) to an amphiphilic α-helical leucine (L)- and lysine (K)-rich CPP (LK) and intranasally delivered it to the interior of nasal epithelial cells for inhibiting epithelial-to-mesenchymal transition (EMT) caused by hypoxia-inducible factor 1α. The RSV-LK conjugate could penetrate into the nasal epithelium and efficiently inhibit EMT, nasal polyp formation, epithelial disruption, and related inflammation in an eosinophilic CRSwNP mouse model, at 10-fold lower doses and with 3-fold less frequent administration than free RSV. Due to the rapid penetration into the nasal epithelium and the therapeutic effect of the RSV-LK conjugate at much lower doses than free RSV, this CPP-based delivery system, with the ability to overcome the tight nasal epithelial barrier, may provide a new strategy for the treatment of localized nasal diseases without the systemic side effects of cargo drugs.

AB - In the present study, we examined the potential of cell-penetrating peptide (CPP)-based intranasal drug delivery for the treatment of localized nasal diseases. Many charged or non-hydrophobic drugs have difficulty penetrating into the nasal epithelium due to intrinsic membrane impermeability and rapid mucociliary clearance in the nasal cavity. To treat chronic rhinosinusitis with nasal polyps (CRSwNP), one of the most common localized nasal diseases, we conjugated resveratrol (RSV) to an amphiphilic α-helical leucine (L)- and lysine (K)-rich CPP (LK) and intranasally delivered it to the interior of nasal epithelial cells for inhibiting epithelial-to-mesenchymal transition (EMT) caused by hypoxia-inducible factor 1α. The RSV-LK conjugate could penetrate into the nasal epithelium and efficiently inhibit EMT, nasal polyp formation, epithelial disruption, and related inflammation in an eosinophilic CRSwNP mouse model, at 10-fold lower doses and with 3-fold less frequent administration than free RSV. Due to the rapid penetration into the nasal epithelium and the therapeutic effect of the RSV-LK conjugate at much lower doses than free RSV, this CPP-based delivery system, with the ability to overcome the tight nasal epithelial barrier, may provide a new strategy for the treatment of localized nasal diseases without the systemic side effects of cargo drugs.

KW - Cell-penetrating peptide

KW - Chronic rhinosinusitis

KW - Epithelial-to-mesenchymal transition

KW - Intranasal delivery

KW - Resveratrol

UR - http://www.scopus.com/inward/record.url?scp=85075800593&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.11.034

DO - 10.1016/j.jconrel.2019.11.034

M3 - Article

C2 - 31785303

AN - SCOPUS:85075800593

VL - 317

SP - 181

EP - 194

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -